Stockscreener 앱 받기
37.07
2.83%
1.02
Genmab Adr 주식(GMAB)의 최신 뉴스
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members - The Manila Times
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL - Zacks Investment Research
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength? - Zacks Investment Research
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Genmab stock gains 5.32 percent on Rina-S data - AD HOC NEWS
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma - GlobeNewswire Inc.
Genmab stock after-hours at EUR 319.90: minus 0.03 percent versus the prior close at Lang & Schwarz - AD HOC NEWS
Genmab reports Rina-S results. Genmab stock falls 1.95 percent - AD HOC NEWS
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewswire Inc.
Major Shareholder Announcement - GlobeNewswire Inc.
HC Wainwright keeps Buy on Genmab stock at USD 40 target - AD HOC NEWS
Genmab stock last trades at DKK 2,282.00 on September 28, 2026 - AD HOC NEWS
Genmab stock at DKK 2,277 on September 25, 2026, up 0.40 percent - AD HOC NEWS
Genmab stock gains 0.8 percent ahead of the open - AD HOC NEWS
Grant of Restricted Stock Units and Warrants to Employees in Genmab - GlobeNewswire Inc.
Genmab stock heads into the open after a 0.84 percent gain - AD HOC NEWS
Genmab stock gains as Kempen raises target to DKK 3,300 - AD HOC NEWS
Genmab stock heads into the open after a 10.80 percent year gain - AD HOC NEWS
Genmab stock advances as Q4 readouts stay on track - AD HOC NEWS
Genmab stock holds steady after first-half 2026 earnings update - AD HOC NEWS
Genmab stock gains as petosemtamab and Q2 figures draw focus - AD HOC NEWS
Genmab stock gains as petosemtamab Phase 3 start and strong Q2 figures support valuation - AD HOC NEWS
Genmab stock heads into the open after a modest gain - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts Q3 earnings estimates and Phase 3 petosemtamab trial begin - AD HOC NEWS
Genmab stock gains as HC Wainwright lifts earnings estimates and confirms Buy rating - AD HOC NEWS
Genmab stock heads into the open after a 1.6% gain in Copenhagen - AD HOC NEWS
Coloplast stock edges lower despite strong quarterly profit surge - AD HOC NEWS
Genmab stock gains support as Barclays lifts target after warrant-driven share issue - AD HOC NEWS
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider - GlobeNewswire Inc.
symbol__ Stock Quote Price and Forecast - CNN
Capital Increase in Genmab as a Result of Employee Warrant Exercise - GlobeNewswire Inc.
Notice to Convene an Extraordinary General Meeting of Genmab A/S - The Manila Times
ETFs Investing in Genmab A/S Sponsored ADR Stocks - TradingView
Genmab stock holds steady as analysts stick to a moderate buy view - AD HOC NEWS
Genmab A/S ADSADR Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesCost Structure Review - careplusvn.com
Genmab (GMAB) Q2 2026 Earnings: EPS Surges 36.6% Past EstimatesGAAP Earnings Report - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingPCR Mean Reversion - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingMarket Cap Weight - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingValue Stock Ideas - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingWave Truncation - dars.gov.et
Genmab A/S (GMAB) Slips 0.21% to $33.16 Amid Range-Bound TradingLow Vol Factor - dars.gov.et
Genmab stock holds in the mid-$30s as higher 2026 guidance leans on royalty income - ad-hoc-news.de
Genmab A/S ADSADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Genmab stock steadies as 2026 royalty-driven guidance lifts revenue outlook - AD HOC NEWS
Genmab A/S ADSADR Key Financial Ratios – Valuation, Profitability & More - valueresearchonline.com
Genmab stock holds steady as 2026 royalty-driven guidance is raised - ad-hoc-news.de
Genmab (GMAB) Snapshot: Finishes 1.05% Lower at $33.10 in the Latest Session; Price Context - dars.gov.et
Genmab (GMAB) Snapshot: Finishes 1.05% Lower at $33.10 in the Latest Session; Price Context - dars.gov.et
Genmab stock climbs on a new $40 call and a 14.57% target gap - Ad-hoc-news.de
0.04%
자본화:
|
볼륨(24시간):